Free shipping on all orders over $ 500


Cat. No. M2952
PMSF  Structure

Phenylmethylsulfonyl Fluoride

Size Price Availability Quantity
Free Sample (0.5-1 mg)  USD 0 In stock
100mg USD 45  USD45 In stock
200mg USD 55  USD55 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

PMSF (Phenylmethyl sulfonyl fluoride) is an irreversible serine/cysteine protease inhibitor. PMSF rapidly inactivates purified chymotrypsin from human pancreas, although human trypsin is less susceptible to inhibition by PMSF. C14-labeled PMSF penetrates human red cells rapidly and inhibits acetylcholinesterase in situ. PMSF is known as phospholipase C inhibitor and also as acetylcholine esterase inhibitor. PMSF inhibits arachidonic acid release during first 4 minutes of ischemia. PMSF inhibits acetylcholine esterase activity in the early stage of complete cerebral ischemia, and induces an inhibition of increase of extracellular glutamate level. PMSF inhibits the addition of ethanolamine phosphate to glycosylphosphatidylinositol (GPI) intermediates in Trypanosoma brucei. PMSF also inhibits the acylation of the inositol residue of GPI intermediates in bloodstream form T. brucei. PMSF is capable of altering the actions of anandamide in vitro by blocking its metabolism. Administration of PMSF in vivo produces cannabinoid effects by altering endogenous levels of anandamide and potentiates the effects of exogenously administered anandamide. [4] Administration of PMSF can induce both promotion and protection in organophosphorus ester-induced delayed neuropathy (OPIDN) in hens. Pretreatment with PMSF results in a leftward shift of the anandamide dose effect curves for antinociception and hypothermia in male mice. Acetylcholinesterase (AChE), a serine hydrolase, is potentially susceptible to inactivation by PMSF. Pretreatment with PMSF protects against the degradation of neurofilaments in tri-ortho-cresyl phosphate (TOCP) induced delayed neuropathy in hens. PMSF treatment enhances the behavioral effects of endogenous and exogenous cannabinoid agonists in mice or rats.

Product Citations
Chemical Information
Molecular Weight 174.19
Formula C7H7FO2S
CAS Number 329-98-6
Solubility (25°C) DMSO ≥ 40 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.


[1] Ehsan Asadi Akbarabadi, et al. PMSF Attenuates Morphine Antinociceptive Tolerance and Dependence in Mice: Its Association with the Oxidative Stress Suppression

[2] Gabriel S Santos, et al. Prolyl Endopeptidase-Like Facilitates the α-Synuclein Aggregation Seeding, and This Effect Is Reverted by Serine Peptidase Inhibitor PMSF

[3] T Irie, et al. Evaluation of phenylmethanesulfonyl fluoride (PMSF) as a tracer candidate mapping acetylcholinesterase in vivo

[4] C Pinsky, et al. Phenylmethylsulfonyl fluoride (PMSF) given systemically produces naloxone-reversible analgesia and potentiates effects of beta-endorphin given centrally

[5] M C Sekar, et al. Differential effects of phenylmethanesulfonyl fluoride (PMSF) on carbachol and potassium stimulated phosphoinositide turnover and contraction in longitudinal smooth muscle of guinea pig ileum

Related Proteasome Products
Zetomipzomib maleate

Zetomipzomib (KZR-616) maleate is a first-in-class inhibitor of immunoproteasome that selectively targets the immunoproteasome subunit LMP7 (IC50: 39/57 nM=hLMP7/mLMP7) and LMP2 (IC50:131/179 nM=hLMP7/mLMP7). Potential of Zetomipzomib maleate for use in multiple autoimmune diseases.


LXE408 is an oral antileishmanarial compound that selectively targets the kinetoplastid proteosome vs. the mammalian proteosome.


Zetomipzomib (KZR-616) is the first immunoproteasome inhibitor that selectively targets the immunoproteasome subunits LMP7 (IC50: 39/57 nM=hLMP7/mLMP7) and LMP2 (IC50: 131/179 nM=hLMP7/mLMP7). Zetomipzomib has potential for use in a variety of autoimmune diseases.


PI-1840 is a reversible and selective chymotrypsin-like (CT-L) inhibitor with IC50 of 27 nM with little effects on the other two major proteasome proteolytic activities, trypsin-like (T-L) and postglutamyl-peptide-hydrolysis-like (PGPH-L).

Ixazomib Citrate (MLN9708)

Ixazomib Citrate (MLN9708) immediately hydrolyzed to MLN2238, the biologically active form, on exposure to aqueous solutions or plasma. MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50/Ki of 3.4 nM/0.93 nM in cell-free assays, less potent to β1 and little activity to β2. Phase 3.

Abmole Inhibitor Catalog

Keywords: PMSF , Phenylmethylsulfonyl Fluoride supplier, Proteasome, inhibitors, activators

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.